It is therefore warranted to further develop SH-1028 as an alternative therapeutic agent for NSCLC patients who acquired resistance to first-generation EGFR TKIs or those with EGFR mutation-positive advanced NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.